Ongoing chromothripsis underpins osteosarcoma genome complexity and clonal evolution

Jose Espejo Valle-Inclán(European Bioinformatics Institute), Solange De Noon(Royal National Orthopaedic Hospital), Katherine Trevers(Royal National Orthopaedic Hospital), Hillary Elrick(European Bioinformatics Institute), Ianthe A. E. M. van Belzen(European Bioinformatics Institute), Sonia Zumalave(European Bioinformatics Institute), Carolin M. Sauer(European Bioinformatics Institute), M. Tanguy(Genomics England), Thomas Butters(Royal National Orthopaedic Hospital), Francesc Muyas(European Bioinformatics Institute), Alistair G. Rust(European Bioinformatics Institute), Fernanda Amary(Royal National Orthopaedic Hospital), Roberto Tirabosco(Royal National Orthopaedic Hospital), Adam Giess(Genomics England), Alona Sosinsky(Genomics England), Greg Elgar(Genomics England), Adrienne M. Flanagan(Royal National Orthopaedic Hospital), Isidro Cortés‐Ciriano(European Bioinformatics Institute)
Cell
January 1, 2025
Cited by 64Open Access
Full Text

Abstract

Osteosarcoma is the most common primary cancer of the bone, with a peak incidence in children and young adults. Using multi-region whole-genome sequencing, we find that chromothripsis is an ongoing mutational process, occurring subclonally in 74% of osteosarcomas. Chromothripsis generates highly unstable derivative chromosomes, the ongoing evolution of which drives the acquisition of oncogenic mutations, clonal diversification, and intra-tumor heterogeneity across diverse sarcomas and carcinomas. In addition, we characterize a new mechanism, termed loss-translocation-amplification (LTA) chromothripsis, which mediates punctuated evolution in about half of pediatric and adult high-grade osteosarcomas. LTA chromothripsis occurs when a single double-strand break triggers concomitant TP53 inactivation and oncogene amplification through breakage-fusion-bridge cycles. It is particularly prevalent in osteosarcoma and is not detected in other cancers driven by TP53 mutation. Finally, we identify the level of genome-wide loss of heterozygosity as a strong prognostic indicator for high-grade osteosarcoma.


Related Papers